Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

$24.99

Analysis of Solvency Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Solvency Ratios (Summary)

Regeneron Pharmaceuticals Inc., solvency ratios (quarterly data)

Microsoft Excel
Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Debt Ratios
Debt to equity
Debt to capital
Debt to assets
Financial leverage
Coverage Ratios
Interest coverage

Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).


The analysis of the financial ratios over the observed periods reveals several noteworthy trends and patterns. These ratios serve to assess the company's leverage, solvency, and ability to meet interest obligations.

Debt to Equity Ratio
This ratio exhibits a general decline over time, starting at 0.06 in March 2020 and decreasing to 0.09 by March 2025. After peaking around 0.27 in September 2020, it shows a sustained downward trend, stabilizing below 0.1 in the most recent periods. This indicates a gradual reduction in reliance on debt financing relative to equity.
Debt to Capital Ratio
Similar to debt to equity, the debt to capital ratio decreases from 0.06 in March 2020 to 0.08 by March 2025. It peaks early at 0.21 in September 2020 before steadily declining. The sustained decline suggests an improvement in capital structure with reduced debt proportion in total financing.
Debt to Assets Ratio
This ratio decreases from 0.05 in March 2020 to 0.07 in March 2025, showing minor fluctuations but an overall decline after an early peak of 0.17 in September 2020. This trend points to a reduction in debt relative to total assets, enhancing asset-backed solvency.
Financial Leverage Ratio
The financial leverage ratio trends downward from 1.3 in March 2020, peaking at 1.59 in June and September 2020, then gradually declining and stabilizing around 1.28 to 1.29 in the last few periods. This indicates a modest reduction in the use of debt financing and controlled leverage over time.
Interest Coverage Ratio
Interest coverage starts with missing values before March 2020 but shows very high values thereafter, beginning at 67.97 in December 2020 and peaking at 163.75 in June 2021. It then declines progressively to around 58.52 in June 2024, followed by an upward recovery reaching 105.27 by March 2025. The generally high values indicate a strong ability to cover interest expenses, despite some volatility in the mid to later periods.

Overall, the data suggest a prudent management of debt levels, with a clear trend toward lower leverage and enhanced solvency. The strength in interest coverage ratios reflects robust earnings relative to interest expenses, supporting financial stability. The initial peak in leverage and debt ratios in mid-2020 may reflect temporary financing activities that were successfully moderated in subsequent periods.


Debt Ratios


Coverage Ratios


Debt to Equity

Regeneron Pharmaceuticals Inc., debt to equity calculation (quarterly data)

Microsoft Excel
Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in thousands)
Debt
Finance lease liabilities, current portion
Long-term debt
Finance lease liabilities, excluding current portion
Total debt
 
Stockholders’ equity
Solvency Ratio
Debt to equity1
Benchmarks
Debt to Equity, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q1 2025 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity
= ÷ =

2 Click competitor name to see calculations.


The financial data reveals several notable trends in the company's capital structure over the examined periods.

Total Debt
The total debt experienced a significant increase from US$715.2 million at the end of Q1 2020 to approximately US$2.7 billion by Q4 2020, after which it remained relatively stable, fluctuating only slightly around the US$2.7 billion mark through to Q1 2025. This suggests a substantial debt issuance or refinancing event early in the period, followed by consistent management of debt levels thereafter.
Stockholders’ Equity
Stockholders’ equity showed a general upward trajectory throughout the period, starting at approximately US$12.13 billion in Q1 2020, declining initially during mid-2020 to about US$9.06 billion in Q2 2020, then recovering and increasing steadily to reach nearly US$29.39 billion by Q1 2025. The initial dip may reflect impacts during the early stages of 2020, followed by sustained equity growth indicating profitable operations, retained earnings, and/or equity issuances strengthening the equity base over time.
Debt to Equity Ratio
The debt to equity ratio exhibited a declining trend across the timeframe, beginning at 0.06 in Q1 2020 and peaking at 0.27 in Q3 2020, which corresponds with the rise in total debt and momentary equity reduction. Subsequently, the ratio continuously decreased to 0.09 by Q1 2025, reflecting a stronger equity position relative to debt. This decline indicates improved leverage metrics and potentially enhanced financial stability with greater reliance on equity financing relative to debt.

Overall, the company's financial stance shows a stabilization of debt following a sharp increase in early 2020, combined with consistent growth in equity and an improving debt to equity ratio. These trends point toward a strengthening balance sheet and a prudent approach to managing financial leverage over the period analyzed.


Debt to Capital

Regeneron Pharmaceuticals Inc., debt to capital calculation (quarterly data)

Microsoft Excel
Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in thousands)
Debt
Finance lease liabilities, current portion
Long-term debt
Finance lease liabilities, excluding current portion
Total debt
Stockholders’ equity
Total capital
Solvency Ratio
Debt to capital1
Benchmarks
Debt to Capital, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q1 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =

2 Click competitor name to see calculations.


The analysis of the financial data indicates distinct trends in the company’s debt levels, capital structure, and leverage ratios over the examined periods.

Total Debt
The total debt figure shows a substantial increase from March 31, 2020, to June 30, 2020, rising sharply from approximately 715 million USD to over 2.2 billion USD. From this point onwards, total debt remains relatively stable around the 2.7 billion USD mark, with only minor incremental increases observed through to March 31, 2025. This suggests that following the initial significant rise, the company has maintained a consistent debt level without further major borrowing or debt repayments.
Total Capital
Total capital exhibits a generally upward trajectory throughout the periods indicated. Starting at nearly 12.8 billion USD at the end of March 2020, there is a slight dip by June 30, 2020, but the metric recovers and increases steadily from September 30, 2020, onwards, reaching over 32 billion USD by March 31, 2025. This consistent growth in total capital implies robust capitalization efforts and possible retained earnings or equity financing contributing to the company's expanding capital base.
Debt to Capital Ratio
The debt to capital ratio experiences a notable increase from 0.06 at the end of March 2020 to a peak of 0.21 by September 30, 2020, reflecting the significant rise in debt observed earlier. However, following this peak, the ratio steadily declines over the subsequent years, decreasing from 0.20 at year-end 2020 to 0.08 by March 31, 2025. This decline indicates a strengthening balance sheet with a reduction in leverage relative to total capital, suggesting improved financial stability or increased equity infusion mitigating the relative weight of debt.

Overall, the data reflects an initial period of increased borrowing followed by a prolonged phase of stable debt and growing capital. The declining debt to capital ratio underlines an enhancement in financial leverage and capital structure quality over time.


Debt to Assets

Regeneron Pharmaceuticals Inc., debt to assets calculation (quarterly data)

Microsoft Excel
Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in thousands)
Debt
Finance lease liabilities, current portion
Long-term debt
Finance lease liabilities, excluding current portion
Total debt
 
Total assets
Solvency Ratio
Debt to assets1
Benchmarks
Debt to Assets, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q1 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =

2 Click competitor name to see calculations.


The financial data reveals distinct trends in total debt, total assets, and the debt to assets ratio over the course of multiple quarterly periods.

Total Debt
The total debt experienced a significant increase from the beginning in March 31, 2020, at approximately $715 million to a peak around June 30, 2020, reaching over $2.2 billion. Following this sharp rise, the debt level stabilized and remained relatively constant at about $2.7 billion from late 2020 through the end of the observed periods in March 31, 2025. This suggests a period of debt accumulation early on, followed by a phase of maintaining a steady debt level.
Total Assets
Total assets exhibited steady growth throughout the time series. Starting from about $15.8 billion in March 2020, there was an initial dip through mid-2020 but losses were quickly recovered, with assets increasing consistently thereafter. By the end of the dataset in March 2025, total assets had grown to roughly $37.5 billion. This upward trajectory indicates ongoing asset expansion, reflecting potential increases in investment, capital expenditures, or retained earnings.
Debt to Assets Ratio
The debt to assets ratio started at a low level of 0.05 in March 2020 and spiked to 0.15-0.17 during mid to late 2020, coinciding with the steep increase in total debt and the temporary asset contraction during the same period. From late 2020 onwards, the ratio demonstrated a downward trend, progressively decreasing to around 0.07 by March 2025. This declining ratio over time, despite the relatively stable debt amount, is mainly driven by the consistent growth in total assets, indicating improved financial leverage and a stronger asset base relative to debt.

Overall, the data suggests that after an initial debt build-up in early 2020, the company has managed to control its debt level while significantly expanding its asset base, leading to improved balance sheet strength and reduced leverage risk over the analyzed quarters.


Financial Leverage

Regeneron Pharmaceuticals Inc., financial leverage calculation (quarterly data)

Microsoft Excel
Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in thousands)
Total assets
Stockholders’ equity
Solvency Ratio
Financial leverage1
Benchmarks
Financial Leverage, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q1 2025 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity
= ÷ =

2 Click competitor name to see calculations.


The financial data reveals distinct trends in the total assets, stockholders’ equity, and financial leverage ratios over the observed quarters.

Total Assets
Total assets showed a fluctuating yet generally increasing trend from March 2020 to March 2025. Initially, assets declined from approximately $15.76 billion in March 2020 to about $14.43 billion in June 2020. After this dip, there was a steady rise, reaching a peak near $37.76 billion in December 2024, before slightly decreasing to approximately $37.55 billion by March 2025. This indicates overall growth in asset base with minor fluctuations.
Stockholders’ Equity
Stockholders’ equity demonstrated a similar upward trajectory, though with more pronounced volatility in the early periods. Starting at $12.13 billion in March 2020, equity dropped sharply to $9.06 billion by June 2020. Subsequently, it steadily increased, nearly tripling over five years to approximately $29.39 billion by December 2024. The growth slowed approaching the latest quarters, stabilizing around $29.39 billion to $29.39 billion by March 2025, suggesting improvements in retained earnings or capital infusions.
Financial Leverage
The financial leverage ratio started relatively low at 1.3 in March 2020 but increased to around 1.59 by mid-2020, indicating a higher proportion of debt relative to equity during that period. From late 2020 onwards, this ratio steadily declined, settling around 1.28 by March 2025. This downward trend reflects a gradual reduction in reliance on debt financing relative to equity, signaling a strengthening equity position alongside asset growth.

Overall, the trends indicate a strengthening financial position with growing assets and equity alongside reduced financial leverage. Early volatility in equity and leverage ratios stabilized in subsequent periods, reflecting improved capital structure and possibly conservative financial management or increased profitability. The slight dip in total assets near the end of the period warrants attention but does not significantly alter the overall growth pattern.


Interest Coverage

Regeneron Pharmaceuticals Inc., interest coverage calculation (quarterly data)

Microsoft Excel
Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in thousands)
Net income
Add: Income tax expense
Add: Interest expense
Earnings before interest and tax (EBIT)
Solvency Ratio
Interest coverage1
Benchmarks
Interest Coverage, Competitors2
Amgen Inc.
Danaher Corp.
Gilead Sciences Inc.
Johnson & Johnson
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q1 2025 Calculation
Interest coverage = (EBITQ1 2025 + EBITQ4 2024 + EBITQ3 2024 + EBITQ2 2024) ÷ (Interest expenseQ1 2025 + Interest expenseQ4 2024 + Interest expenseQ3 2024 + Interest expenseQ2 2024)
= ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The earnings before interest and tax (EBIT) for the company exhibit notable fluctuations over the observed periods. Initially, EBIT showed a robust upward trend from March 31, 2020, reaching a peak in June 30, 2021, at 3,767,200 thousand US dollars. This peak is significantly higher than the general range observed in other quarters, indicating either exceptional operational performance or one-time events favorably impacting earnings. Following this peak, EBIT declined considerably in the subsequent quarter but maintained a level above one million US dollars until the end of 2022.

In 2023, EBIT values become somewhat more variable, fluctuating between approximately 876,000 and 1,165,900 thousand US dollars across the quarters. In 2024, EBIT again showed an increase, peaking at 1,642,900 thousand US dollars in June, followed by a decline in the subsequent quarters. By March 31, 2025, the EBIT declined to 913,700 thousand US dollars, indicating a decrease compared to the heights seen in mid-2024 but still within a moderate range compared to historical values.

Interest expense remained relatively stable throughout the entire period, fluctuating narrowly between around 6,100 thousand US dollars in early 2020 and a high of 18,900 thousand US dollars in June 2023. In the more recent quarters up to March 31, 2025, interest expense trends downward, falling to 8,700 thousand US dollars, suggesting reduced borrowing costs or decreased debt levels.

The interest coverage ratio, calculated as EBIT divided by interest expense, underscores strong capacity to cover interest obligations. The ratio was exceptionally high, with values exceeding 60 from late 2020 onward, reaching above 100 during mid-2021. This indicates an excellent ability to service debt interest relative to earnings. Despite fluctuations in EBIT, the strong coverage ratios suggest that the company maintained a robust buffer for interest payments throughout the period. In the final quarters up to March 2025, the interest coverage improved further, surpassing 100 again, reinforcing the strength of profitability relative to financing costs.

Overall, the financial data reveal a company with volatile but predominantly strong operational earnings supported by comparatively stable and manageable interest expenses. The exceptional EBIT peak in mid-2021 stands out as an unusual positive spike. Interest coverage ratios consistently indicate effective management of interest obligations, highlighting a financially sound position in terms of earnings relative to debt servicing.